With over 200 special purpose acquisition company SPAC IPOs and over 100 SPAC mergers and counting over the last year, SPACs are hotter than ever. But are they the right approach for most Life Sciences companies seeking capital? 

Join BDO and McDermott Will & Emery for a discussion with Anna Marie Wagner, Senior Vice President, Corporate Development of Ginkgo Bioworks, around SPACs in the Life Sciences industry. 

We’ll discuss:

• How to evaluate whether a SPAC is the right capital raising vehicle

• How the new administration has affected the SPAC market

• Accounting considerations that can potentially derail valuation

• How to mitigate risks and challenges associated with a SPAC deal